KRAS and non-small cell lung carcinoma: To this aim, we retrospectively evaluated data collected from our archives of advanced stage NSCLC patients with positive PD-L1 expression (≥1%) who were referred to our clinic for evaluation of at least five of the most common driver mutations, namely, EGFR, KRAS, BRAF, ALK and ROS1.